Archaeosome adjuvants: Immunological capabilities and mechanism(s) of action

Vaccine

Volumn 26, Issue 17, 2008, Pages 2043-2055

  Krishnan, Lakshmi ^a   Sprott, G Dennis ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Adjuvants; Antigen delivery systems; Antigen presentation; CD8 T cell response; Immune memory; Liposomes; Vaccination

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ARCHAEOSOME; BACTERIAL VACCINE; CANCER VACCINE; CHOLESTEROL; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; GAMMA INTERFERON; GLYCEROLIPID; GLYCOPROTEIN GP 100; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; LIPOSOME; LISTERIOLYSIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; MELANOMA ANTIGEN; OVALBUMIN; PHOSPHATIDYLSERINE; QUIL A; TRANSACTIVATOR PROTEIN; TYROSINASE RELATED PROTEIN 2; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARCHAEBACTERIUM; BIOCOMPATIBILITY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOSOL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG STABILITY; DRUG STRUCTURE; HALOBACTERIUM SALINARUM; HALOFERAX VOLCANII; HUMORAL IMMUNITY; IMMUNOREGULATION; INFECTION; LISTERIOSIS; LUNG TUMOR; MELANOMA; MEMORY T LYMPHOCYTE; METHANOBACTERIUM; METHANOBACTERIUM ESPANOLAE; METHANOBREVIBACTER SMITHII; METHANOSAETA CONCILII; METHANOSARCINA MAZEI; METHANOSPHAERA STADTMANAE; METHANOSPIRILLUM HUNGATEI; NEOPLASM; NONHUMAN; PHAGOSOME; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TH1 CELL; TH2 CELL; THERMOPLASMA ACIDOPHILUM; UPREGULATION; VIRUS LIKE AGENT;

ADJUVANTS, IMMUNOLOGIC; ADJUVANTS, PHARMACEUTIC; ANTIGEN PRESENTATION; ARCHAEA; CHEMISTRY, PHYSICAL; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; LIPOSOMES; VACCINES;

EID: 41549168194     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.02.026     Document Type: Review

References (88)

1. Esser M.T., Marchese R.D., Kierstead L.S., Tussey L.G., Wang F., Chirmule N., et al. Memory T cells and vaccines. Vaccine 21 5-6 (2003) 419-430
2. + T-cell memory in tumor immunology and immunotherapy. Immunol Rev 211 (2006) 214-224
3. Medina E., and Guzman C.A. Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine 19 13-14 (2001) 1573-1580
4. Roland K.L., Tinge S.A., Killeen K.P., and Kochi S.K. Recent advances in the development of live, attenuated bacterial vectors. Curr Opin Mol Ther 7 1 (2005) 62-72
5. Pym A.S., Brodin P., Majlessi L., Brosch R., Demangel C., Williams A., et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 9 5 (2003) 533-539
6. Kundig T.M., Kalberer C.P., Hengartner H., and Zinkernagel R.M. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 11 11 (1993) 1154-1158
7. Dudani R., Chapdelaine Y., van Faassen H., Smith D.K., Shen H., Krishnan L., et al. Preexisting inflammation due to Mycobacterium bovis BCG infection differentially modulates T-cell priming against a replicating or nonreplicating immunogen. Infect Immun 70 4 (2002) 1957-1964
8. Leclerc C., and Ronco J. New approaches in vaccine development. Immunol Today 19 7 (1998) 300-302
9. Selin L.K., Lin M.Y., Kraemer K.A., Pardoll D.M., Schneck J.P., Varga S.M., et al. Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. Immunity 11 6 (1999) 733-742
10. Pashine A., Valiante N.M., and Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 11 4 Suppl (2005) S63-S68
11. O'Hagan D.T., and Valiante N.M. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2 9 (2003) 727-735
12. Alving C.R. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 20 Suppl 3 (2002) S56-S64
13. Ben Ahmeida E.T., Gregoriadis G., Potter C.W., and Jennings R. Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice. Vaccine 11 13 (1993) 1302-1309
14. Lowell G.H., Kaminski R.W., VanCott T.C., Slike B., Kersey K., Zawoznik E., et al. Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: induction of serum, intestinal, vaginal, and lung IgA and IgG. J Infect Dis 175 2 (1997) 292-301
15. Rock K.L., and Goldberg A.L. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 17 (1999) 739-779
16. Harding C.V., and Geuze H.J. Immunogenic peptides bind to class II MHC molecules in an early lysosomal compartment. J Immunol 151 8 (1993) 3988-3998
17. Mosmann T.R., and Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17 3 (1996) 138-146
18. Sad S., and Krishnan L. Maintenance and attrition of T-cell memory. Crit Rev Immunol 23 1-2 (2003) 129-147
19. Wherry E.J., Teichgraber V., Becker T.C., Masopust D., Kaech S.M., Antia R., et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 4 3 (2003) 225-234
20. Kaech S.M., Tan J.T., Wherry E.J., Konieczny B.T., Surh C.D., and Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 4 12 (2003) 1191-1198
21. Kaech S.M., Wherry E.J., and Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2 4 (2002) 251-262
22. Sprott G.D., and Krishnan L. Archaeosome vaccines. In: Cavicchioli R. (Ed). Archaea (2007), ASM Press, Washington 496-510
23. Sprott G.D., Patel G.B., and Krishnan L. Archaeobacterial ether lipid liposomes as vaccine adjuvants. Methods Enzymol 373 (2003) 155-172
24. Bligh E.G., and Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37 8 (1959) 911-917
25. Omri A., Makabi-Panzu B., Agnew B.J., Sprott G.D., and Patel G.B. Influence of coenzyme Q10 on tissue distribution of archaeosomes, and pegylated archaeosomes, administered to mice by oral and intravenous routes. J Drug Target 7 5 (2000) 383-392
26. high) phenotype by an archaeosome adjuvant independent of TLR2. J Immunol 178 4 (2007) 2396-2406
27. Sprott G.D., Tolson D.L., and Patel G.B. Archaeosomes as novel antigen delivery systems. FEMS Microbiol Lett 154 1 (1997) 17-22
28. Sprott G.D., Brisson J., Dicaire C.J., Pelletier A.K., Deschatelets L.A., Krishnan L., et al. A structural comparison of the total polar lipids from the human archaea Methanobrevibacter smithii and Methanosphaera stadtmanae and its relevance to the adjuvant activities of their liposomes. Biochim Biophys Acta 1440 (1999) 275-288
29. Krishnan L., Dicaire C.J., Patel G.B., and Sprott G.D. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated and memory responses: comparison to conventional liposomes and alum. Infect Immun 68 1 (2000) 54-63
30. Sprott G.D., Sad S., Fleming L.P., Dicaire C., Patel G.B., and Krishnan L. Archaeosomes varying in lipid composition differ in receptor-mediated endocytosis and differentially adjuvant immune responses to entrapped antigen. Archaea 1 (2003) 151-164
31. Sprott G.D., Dicaire C.J., Gurnani K., Deschatelets L.A., and Krishnan L. Liposome adjuvants prepared from the total polar lipids of Haloferax volcanii, Planococcus spp. and Bacillus firmus differ in ability to elicit and sustain immune responses. Vaccine 22 17-18 (2004) 2154-2162
32. Patel G.B., Zhou H., KuoLee R., and Chen W. Archaeosomes as adjuvants for combination vaccines. J Liposome Res 14 3-4 (2004) 191-202
33. + T lymphocytes. In: Kimber I., and Selgrade M.K. (Eds). T lymphocyte subpopulations in immunotoxicology (1998), John Wiley & Sons, Chichester, UK 7-32
34. Brewer J.M., Conacher M., Hunter C.A., Mohrs M., Brombacher F., and Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol 163 12 (1999) 6448-6454
35. Gupta R.K., Rost B.E., Reyveld R.E., and Siber G.S. Adjuvant properties of aluminum and calcium compounds. In: Powell M.F., and Newman M.J. (Eds). Vaccine design: the subunit and adjuvant approach (1995), Plenum Press, New York 229-248
36. + T cell help. J Immunol 165 (2000) 5177-5185
37. Krishnan L., Sad S., Patel G.B., and Sprott G.D. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge. Cancer Res 63 10 (2003) 2526-2534
38. Gurnani K., Kennedy J., Sad S., Sprott G.D., and Krishnan L. Phosphatidylserine receptor-mediated recognition of archaeosome adjuvant promotes endocytosis and MHC class I cross-presentation of the entrapped antigen by phagosome-to-cytosol transport and classical processing. J Immunol 173 1 (2004) 566-578
39. Conlan J.W., Krishnan L., Patel G.B., and Sprott G.D. Immunization of mice with lipopeptide antigens encapsulated in specialised liposomes prepared from the total polar lipids of various archaeobacteria elicits rapid prolonged protective immunity against the facultative intracellular pathogen Listeria monocytogenes. Vaccine 19 (2001) 3509-3517
40. Krishnan L., and Dennis G.D. Archaeosomes as self-adjuvanting delivery systems for cancer vaccines. J Drug Target 11 8-10 (2003) 515-524
41. Sprott G.D., Dicaire C.J., Gurnani K., Sad S., and Krishnan L. Activation of dendritic cells by liposomes prepared from phosphatidylinositol mannosides from Mycobacterium bovis Bacillus Calmette-Guerin and adjuvant activity in vivo. Infect Immun 72 9 (2004) 5235-5246
42. Sprott G.D., Larocque S., Cadotte N., Dicaire C.J., McGee M., and Brisson J.R. Novel polar lipids of halophilic eubacterium Planococcus H8 and archaeon Haloferax volcanii. Biochim Biophys Acta 1633 (2003) 179-188
43. Cheers C., McKenzie I.F., Pavlov H., Waid C., and York J. Resistance and susceptibility of mice to bacterial infection: course of listeriosis in resistant or susceptible mice. Infect Immun 19 3 (1978) 763-770
44. Edelson B.T., and Unanue E.R. Immunity to Listeria infection. Curr Opin Immunol 12 4 (2000) 425-431
45. Pamer E.G., Harty J.T., and Bevan M.J. Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes. Nature 353 6347 (1991) 852-855
46. + cytotoxic T cells. Vaccine 12 1 (1994) 73-80
47. Ballard J.D., Collier R.J., and Starnbach M.N. Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo. Proc Natl Acad Sci USA 93 22 (1996) 12531-12534
48. Hess J., Gentschev I., Miko D., Welzel M., Ladel C., Goebel W., et al. Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis. Proc Natl Acad Sci USA 93 4 (1996) 1458-1463
49. + T cells in vivo: the key to rational vaccine design. Annu Rev Immunol 23 (2005) 651-682
50. Basta S., and Alatery A. The cross-priming pathway: a portrait of an intricate immune system. Scand J Immunol 65 4 (2007) 311-319
51. Cresswell P., Ackerman A.L., Giodini A., Peaper D.R., and Wearsch P.A. Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol Rev 207 (2005) 145-157
52. Houde M., Bertholet S., Gagnon E., Brunet S., Goyette G., Laplante A., et al. Phagosomes are competent organelles for antigen cross-presentation. Nature 425 6956 (2003) 402-406
53. Ackerman A.L., Kyritsis C., Tampe R., and Cresswell P. Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc Natl Acad Sci USA 100 22 (2003) 12889-12894
54. Suzuki Y., Wakita D., Chamoto K., Narita Y., Tsuji T., Takeshima T., et al. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res 64 23 (2004) 8754-8760
55. Guy B., Pascal N., Francon A., Bonnin A., Gimenez S., Lafay-Vialon E., et al. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine 19 13-14 (2001) 1794-1805
56. Vangasseri D.P., Cui Z., Chen W., Hokey D.A., Falo Jr. L.D., and Huang L. Immunostimulation of dendritic cells by cationic liposomes. Mol Membr Biol 23 5 (2006) 385-395
57. Makabi-Panzu B., Lessard C., Beauchamp D., Desormeaux A., Poulin L., Tremblay M., et al. Uptake and binding of liposomal 2′,3′-dideoxycytidine by RAW 264.7 cells: a three-step process. J Acquir Immune Defic Syndr Hum Retrovirol 8 3 (1995) 227-235
58. Tolson D.L., Latta R.K., Patel G.B., and Sprott G.D. Uptake of archaeobacterial and conventional liposomes by phagocytic cells. J Liposome Res 6 (1996) 755-776
59. Somersan S., and Bhardwaj N. Tethering and tickling: a new role for the phosphatidylserine receptor. J Cell Biol 155 4 (2001) 501-504
60. Kovacsovics-Bankowski M., and Rock K.L. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267 (1995) 243
61. Rodriguez A., Regnault A., Kleijmeer M., Ricciardi-Castagnoli P., and Amigorena S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1 6 (1999) 362-368
62. Collins D.S., Findlay K., and Harding C.V. Processing of exogenous liposome-encapsulated antigens in vivo generates class I MHC-restricted T cell responses. J Immunol 148 11 (1992) 3336-3341
63. Nair S., Zhou F., Reddy R., Huang L., and Rouse B.T. Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. J Exp Med 175 2 (1992) 609-612
64. Fausch S.C., Da Silva D.M., and Kast W.M. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res 63 13 (2003) 3478-3482
65. Leclerc D., Beauseigle D., Denis J., Morin H., Pare C., Lamarre A., et al. Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells. J Virol 81 3 (2007) 1319-1326
66. Moron V.G., Rueda P., Sedlik C., and Leclerc C. In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J Immunol 171 5 (2003) 2242-2250
67. Ruedl C., Storni T., Lechner F., Bachi T., and Bachmann M.F. Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur J Immunol 32 3 (2002) 818-825
68. Storni T., Lechner F., Erdmann I., Bachi T., Jegerlehner A., Dumrese T., et al. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J Immunol 168 6 (2002) 2880-2886
69. Miller T.L., and Wolin M.J. Methanogens in human and animal intestinal tracts. System Appl Microbiol 7 (1986) 223-229
70. Lepp P.W., Brinig M.M., Ouverney C.C., Palm K., Armitage G.C., and Relman D.A. Methanogenic Archaea and human periodontal disease. Proc Natl Acad Sci USA 101 16 (2004) 6176-6181
71. Krishnan L., Sad S., Patel G.B., and Sprott G.D. The potent adjuvant activity of archaeosomes correlates to the recruitment and activation of macrophages and dendritic cells in vivo. J Immunol 166 (2001) 1885-1893
72. + T cell immunity. In: Singh M. (Ed). Vaccine adjuvants and delivery systems (2007), John Wiley & Sons, Hoboken, NJ 263-294
73. Godfrey D.I., Hammond K.J., Poulton L.D., Smyth M.J., and Baxter A.G. NKT cells: facts, functions and fallacies. Immunol Today 11 (2000) 573-583
74. Swain M., Brisson J.R., Sprott G.D., Cooper F.P., and Patel G.B. Identification of beta-l-gulose as the sugar moiety of the main polar lipid Thermoplasma acidophilum. Biochim Biophys Acta 1345 1 (1997) 56-64
75. Freisleben H.J., Bormann J., Litzinger D.C., Lehr F., Rudolph P., Schatton W., et al. Toxicity and biodistribution of liposomes of the main phospholipid from the archaeobacterium Thermoplasma acidophilum. J Liposome Res 5 (1995) 215-223
76. Omri A., Agnew B.J., and Patel G.B. Short-term repeated dose toxicity profile of archaeosomes administered to mice via intravenous and oral routes. Int J Toxicol 22 (2003) 9-23
77. Patel G.B., Omri A., Deschatelets L.A., and Sprott G.D. Safety of archaeosome adjuvants evaluated in a mouse model. J Liposome Res 12 (2002) 353-372
78. Lee T.C. Biosynthesis and possible biological functions of plasmalogens. Biochim Biophys Acta 1394 2-3 (1998) 129-145
79. Tengerdy R.P., and Lacetera N.G. Vitamin E adjuvant formulations in mice. Vaccine 9 3 (1991) 204-206
80. Folkers K., Morita M., and McRee Jr. J. The activities of coenzyme Q10 and vitamin B6 for immune responses. Biochem Biophys Res Commun 193 1 (1993) 88-92
81. Sprott GD, Whitfield DM, Krishnan L. Synthetic archaeal glycolipid adjuvants. Patent application PCT/CA2007/000530, WO/2007/1125672007.
82. Shimada H., Nemoto N., Shida Y., Oshima T., and Yamagishi A. Complete polar lipid composition of Thermoplasma acidophilum HO-62 determined by high-performance liquid chromatography with evaporative light-scattering detection. J Bacteriol 184 2 (2002) 556-563
83. Kushwaha S.C., Kates M., Sprott G.D., and Smith I.C. Novel complex polar lipids from the methanogenic archaebacterium Methanospirillum hungatei. Science 211 4487 (1981) 1163-1164
84. Sprott G.D., Ferrante G., and Ekiel I. Tetraether lipids of Methanospirillum hungatei with head groups consisting of phospho-N,N-dimethylaminopentanetetrol, phospho-N,N,N-trimethylaminopentanetetrol, and carbohydrates. Biochim Biophys Acta 1214 3 (1994) 234-242
85. Nishihara M., and Koga Y. Hydroxyarchaetidylserine and hydroxyarchaetidyl-myo-inositol in Methanosarcina barkeri: polar lipids with a new ether core portion. Biochim Biophys Acta 1082 2 (1991) 211-217
86. Sprott G.D., Dicaire C.J., and Patel G.B. The ether lipids of Methanosarcina mazei and other Methanosarcina species, compared by fast atom bombardment mass spectrometry. Can J Microbiol 40 (1994) 837-843
87. Ferrante G., Ekiel I., Patel G.B., and Sprott G.D. Structure of the major polar lipids isolated from the aceticlastic methanogen, Methanothrix concilii GP6. Biochim Biophys Acta 963 (1988) 162-172
88. Kates M. Structure, physical properties, and function of archaeobacterial lipids. Prog Clin Biol Res 282 (1988) 357-384